Cancer Therapeutics Research Program | UC Davis Comprehensive Cancer Center

Cancer Therapeutics

CTP header

The Cancer Therapeutics Program is a collaborative network of basic scientists and clinical investigators whose research spans the full spectrum from experimental to developmental therapeutics. The program serves as a hub for the translation of cancer-related discoveries into clinical trials, with the ultimate goal of improving patient outcomes across the UC Davis Comprehensive Cancer Center and the communities we serve.

The program is dedicated to identifying new biomarkers and molecular targets for cancer treatment, accelerating the development of promising new therapies, and bridging the gap between preclinical research and patient care through clinical trials. Its efforts include developing and applying innovative tools for biomarker and target discovery, advancing novel imaging techniques and lead compounds, creating new antineoplastic drugs and drug delivery systems, and designing and conducting hypothesis-driven clinical trials grounded in strong preclinical rationale.

View Cancer Therapeutics members

Membership Resources for Researchers

Involved in cancer research? Join UC Davis Comprehensive Cancer Center, the only NCI-designated comprehensive cancer center serving inland Northern California and the Central Valley. Collaborate with top researchers, access resources and contribute to our mission. Open to UC Davis faculty and LLNL researchers with a focused interest in cancer or related disciplines. Learn more about membership and resources.

Cancer Therapeutics Program Leaders
  • Kit S. Lam M.D., Ph.D.

    Distinguished Professor, Department of Biochemistry and Molecular Medicine

    Expertise: drug discovery and development; combinatorial chemistry; nanotechnology; molecular imaging; chemical biology

    View profile
  • Richard Valicenti, M.D., M.A., FASTRO

    Professor and Chair, Department of Radiation Oncology

    Expertise: radiation oncologist specializing in prostate cancer; clinical trialist testing new paradigms for multimodality therapies

    View profile